Purpose: The purpose of this study is to evaluate the diagnostic concordance and metric correlations of amide proton transfer (APT) imaging with gadolinium-enhanced magnetic resonance imaging (MRI) and 2-deoxy- 
Introduction
An increasing number of integrated positron emission tomography (PET)/magnetic resonance imaging (MRI) systems have been introduced into clinical practice in recent years. The combination of PET metabolic and MRI structural as well as functional information provides potential advantages in oncology through whole-body or regional scanning [1] . This is also the case for suspected tumors in the brain, although conventional MRI can provide good morphological assessment, especially with gadolinium (Gd) injection. However, Gd-enhanced MRI is limited in those lesions with an intact blood-brain barrier (BBB), despite the ability to provide functional parameters from perfusion-weighted imaging about tumor angiogenesis. The glucose analog 2-deoxy-2-[ 1 8 18 F]FDG PET/MR clinical scan protocol for brain tumor or tumor-like lesion diagnosis, grading, and staging has yet to be realized.
Regardless of Gd enhancement, another advantage for MR, with regard to brain tumor diagnosis, is the use of multiple functional imaging parameters, including diffusionweighted imaging (DWI) for cellularity, proton MR spectroscopy for cerebral metabolites, and amide proton transfer (APT) imaging for mobile cellular proteins and peptides or pH changes in tissue [4] [5] [6] . It has been shown previously that these different MR metrics are closely related to various pathological features that have been used as diagnostic clues for malignancy differentiation and tumor grading. Among all of the chemical exchange-dependent saturation transfer (CEST) MR imaging techniques, APT imaging has recently become available on clinical 3T MR scanners and has shown great potential in clinics as an important molecular imaging technique [7, 8] 
Materials and Methods

Subjects
From June 2014 through January 2015, subjects were enrolled in this prospective study, which was approved by the local institutional ethics committee and written informed consent was obtained from all subjects. The inclusion criteria were the following: suspected brain lesions on prior CT or MRI referred for further whole-body examinations; no history of treatment, including surgery, radiotherapy, chemotherapy, or corticosteroid administration; no contraindications for Gd-enhanced MRI or PET scanning, such as metallic device implantation, pregnancy or nephropathy; and normal or corrected-to-normal blood glucose level. The exclusion criteria were no final diagnosis from pathology or loss to follow-up. Subjects with inadequate or unclear images due to motion artifacts or technical problems (like image distortion caused by unknown metal implants or image misregistration caused by iatrogenic scanning errors from technicians) were also excluded. Ultimately, 21 subjects were enrolled: 12 male and 9 female patients with a mean age of 54.5 (± 15.5) years, as shown in Table 1 .
Imaging Protocol
All examinations were performed on a clinical Ingenuity TF PET/MR scanner (Philips, Cleveland, OH), which consists of two separate scanners (the Ingenuity Time-of-Flight PET scanner and an Achieva 3T X-series MRI) linked through one rotatable patient table, thus allowing for sequential imaging. After injection with approximately 5.5 MBq/kg body weight [ 18 F]FDG, all subjects would rest in bed for about 40 min with closed eyes and with earplugs in their ears. Then, they underwent whole-body plus Gd-enhanced brain PET/MR scans. The whole-body PET/MR scan included a dedicated T1-weighted fast-field echo sequence (termed atMR) and diagnostic T2-weighted imaging (T2WI) with the Q-Body coil, and a whole-body PET emission acquisition (10 to 12 bed positions, 2 min each). The brain , as well as Gd-enhanced, three-plane T1WI (0.2 ml/kg body weight; Magnevist; Bayer Schering, China). The APT imaging sequence was acquired before the injection of Gd contrast agent. The total duration for one case was about 37 to 40 min.
In the APT imaging part, a single-shot turbo spin-echo sequence was used: repetition time, 3000 ms; sensitivityencoding factor, 2; field of view, 240 mm × 240 mm; matrix, 128 × 64 (reconstructed to be 400 × 400); and slice thickness, 6 mm. A pseudocontinuous wave radiofrequency irradiation (saturation duration, 200 ms × 4; inter-pulse delay, 10 ms; power level, 2 μT) and a multi-offset, multiacquisition CEST/APT imaging protocol were adopted [2] . The 31 offsets were 0 (n = 1), ± 0.25 (n = 1), ± 0.5 (n = 1), ± 0.75 (n = 1), ± 1 (n = 2), ± 1.5 (n = 2), ± 2 (n = 2), ± 2.5 (n = 2), ± 3 (n = 2), ± 3.25 (n = 2), ± 3.5 (n = 8), ±3.75 (n = 2), ± 4 (n = 2), ± 4.5 (n = 1), ± 5 (n = 1), and ± 6 (n = 1) ppm. In order to achieve signal normalization, an unsaturated image was obtained. APT scans were located and acquired at the maximum tumor area, based on T2WI and FLAIR images, with an on-site decision from an experienced radiologist. The acquisition time was about 3 min.
Image Analysis and Statistics
PET and standard MR images were reviewed, fused, and analyzed using an Extended Brilliance Workspace workstation (Philips Healthcare, Cleveland, OH). APT imaging raw data were processed using the Interactive Data Language (IDL; ITT Visual Information Solutions, Boulder, CO, USA). As reported in the literature [11, 12] , the APT imaging raw data were first organized into the z-spectrum. Then, the z-spectrum was fitted on a pixel-by-pixel basis, and the B0 inhomogeneity map was created. After this, the original z-spectrum was corrected for the B0 inhomogeneity effect through the interpolation and centering of the zspectrum. Finally, the APT-weighted (APTW) image was constructed, using the magnetization transfer-ratio asymmetry at the offsets of ± 3.5 ppm. The gold standard for diagnosis reference was histopathologic results and at least 1 year of follow-up imaging.
Three experienced radiologists (with dual board certifications from radiology and nuclear medicine), with no knowledge of the clinical history, independently analyzed the unenhanced MRI (T1WI, T2WI, FLAIR plus DWI), enhanced MRI (T1WI), APT imaging, and [
18 F]FDG PET at four different time points. The interval was at least 2 weeks to minimize recall bias. Six diagnostic criteria were used in this study: tumor detection and confirmation; lesion homogeneity or heterogeneity; presence or absence of necrosis, hemorrhage or liquefaction; good or poor delineation of tumor margins; confirmation of peritumoral edema; and final diagnosis. Table 2 illustrates these diagnostic criteria, based on morphology and final diagnosis, in detail, and a typical case is shown in Fig. 1 . Accuracy for each series of images was calculated on a per-lesion basis. At each time point, a score of 1 was assigned if all three interpreters agreed with the reference, an accuracy of 2/3 or 1/3 was assigned if two or one interpreter, respectively, agreed with the reference, and 0 was assigned if none agreed with the reference. Finally, diagnostic accuracy for every metric was calculated and compared between unenhanced and enhanced MRI, APT imaging and [ 18 F]FDG PET, and enhanced MRI and APT imaging using a paired t test with bias-correction and accelerated bootstrap confidence intervals.
Among the cases diagnosed as tumors, the concordance between APTW signal intensity, Gd enhancement, and [ 18 F]FDG avidity was evaluated lesion-by-lesion, and regions of interest (ROIs) were carefully chosen after all interpreters reached consensus. According to previous studies [12, 13] , ROIs were defined based on Gd enhancement and were delineated on the same Gd-enhanced image slice as the APTW and PET images. In each tumor, at least five ROIs were measured at the enhancing solid part, and an average of the measurements from all these ROIs was taken as the final value for the tumor. Tumor borders, large necrosis, hemorrhage, or vessels were avoided. The maximum APTW intensity (APTW max ), maximum SUV (SUV max ), mean APTW intensity (APTW mean ), and mean SUV (SUV mean ) were recorded for statistical analysis. The McNemar test was used for concordance comparison and the Pearson correlation analysis was used to evaluate the associations between these metrics. Statistical analysis was accomplished with the Statistical Package for the Social Sciences (SPSS, Version 19.0; Chicago, IL, USA). A P value of less than 0.05 was considered statistically significant.
Results
There was no case of image misregistration since no severe head movement occurred during scanning. Among all 21 subjects, 23 lesions were found and finally confirmed, with a diagnostic accuracy of 100 % for [ 18 imaging significantly (P = 0.031). As shown in Figs. 1 and  2 , the tumors (one metastasis and one meningioma) showed concordant enhancement on T1WI, high signal intensity on the APTW image, and high FDG uptake on [ 18 F]FDG PET. Figure 3 presents a difficult case of glioblastoma (WHO grade IV) with a cyst-like appearance and minor septum on unenhanced MRI. Mild ring enhancement indicated a possible malignancy on enhanced MRI, and obvious hyperintensity on the APTW image confirmed the diagnosis of a malignant tumor. The tumor was mildly hypointense compared to the contralateral normal-appearing white matter on [ 18 F]FDG PET, which was mainly used to determine whether it was primary or metastatic after a whole-body examination.
Quantitative Correlations Between APT Imaging and PET
Brain tumors show a variety of [
18 F]FDG uptake patterns, which do not correlate with tumor grade [14] . Thus, we performed a correlation analysis in the tumor subgroups of high [ 18 F]FDG uptake (13 tumors in total with a higher [ 18 F]FDG uptake compared to gray matter and/or white matter uptake, including 11 metastases and two meningiomas) and non-avid [ 18 F]FDG uptake (six tumors including two metastases, three gliomas, and one meningioma). As shown in Fig. 4 , there were significant correlations between APTW max and SUV max (r = 0.609, P = 0.027), as well as between APTW mean and SUV mean (r = 0.599, P = 0.030) for 
Discussion
As a new multiple imaging modality, hybrid PET/MR provides myriad choices in the selection of MRI sequences and contrast medium, as well as in PET radiotracers, in order to provide different aspects of pathophysiological information in lesions simultaneously. However, some procedures or information might be repetitive and unnecessary. Thus, the optimization of a PET/MR protocol and clarification of the relations between different modalities are mandatory for both routine clinical use and scientific research [15] NA not applicable *Represents significant difference since the confidence interval does not straddle 0
Compared to conventional unenhanced MRI and [ 18 F]FDG PET in the brain, Gd-enhanced imaging has traditionally been a superior method for lesion detection, differentiation, and final diagnosis, which was also shown in our study. The principle of contrast-enhanced imaging is based on the high concentration of contrast agent in blood vessels and in brain lesions with a BBB leak. However, functional imaging techniques, like DWI and the other novel method, APT imaging, were involved in this study to make a comparison among different techniques. DWI can reflect information about the extracellular space and cell density, which has routinely been used for the diagnosis and treatment evaluation of stroke and tumors in the clinic. APT imaging is based on the CEST signal of mobile proteins and peptides at the offset of 3.5 ppm from water, which can reflect pH information in stroke and detect endogenous mobile proteins and peptides in tumors noninvasively [3] . In contrast to a Gd chelate as an exogenous contrast medium, APT imaging, as a functional molecular imaging technique involving endogenous contrast, has become more and more useful in the evaluation and differentiation of brain lesions, including stoke, tumors, and degenerative diseases [6, 16] . Previous studies have confirmed a complementary role for APT imaging to standard MRI sequences after a direct comparison of brain tumor presentation between APTW, diffusion, and Gdenhanced images [17, 18] . Other recent studies demonstrated an added value of APT imaging in grading glioma and differentiating tumor recurrence from radiation necrosis, where Gd-enhanced imaging is not beneficial [19] [20] [21] . In accordance with these studies, we found that APT imaging and Gd-enhanced imaging were concordant and comparably superior to [ 18 F]FDG PET/MR in brain tumor detection and diagnosis. APT imaging showed an inferior ability to illustrate tumor heterogeneity and tumor components, compared to Gd-enhanced imaging, such as necrosis, hemorrhage, or liquefaction tissue, which might also be proteinaceous. However, standard unenhanced MRI can compensate for this shortcoming since these sequences are usually analyzed together in routine practice [22] . Thus, our study demonstrated promising results after applying APT imaging on a clinical PET/MR scanner. With the help of APT imaging, the unnecessary administration of Gd contrast will avoid the incidence of nephrogenic sclerosis and gadolinium chelate deposition in the brain [23, 24] [4] . In our study, we had two meningiomas of high [ 18 F]FDG uptake, which were ultimately confirmed as WHO grade I tumors by pathology (Fig. 2) . [ 18 F]FDG uptake of brain meningiomas is related to cellular proliferative activity and recurrence rate, rather than tumor grading [26] . The other main reason is the relatively high background glucose uptake within the normal brain. In this study, in addition to the one high-grade glioma (WHO grade IV) of mild [ 18 F]FDG hypometabolism (Fig. 3) , we also found a suboptimal sensitivity for [ 18 F]FDG PET in the detection of brain metastases (84.6 %, 11/13). This may be attributable to the interplay of two factors: the hypometabolic nature of some tumors and the intense physiologic background uptake. Thus, this could explain the fact that there were no correlations between the metrics from APT imaging and [ 18 18 F]FDG-positive lesions. There are still some limitations to our study. First, the sample size was not large enough. The clinical workflow and indications for PET/MR are currently under investigation, with the goal of optimization among different centers, which will result, hopefully, in large-scale prospective studies in the near future. Second, tumors without Gd enhancement, such as atypical glioblastomas and anaplastic astrocytoma, were not included in this study [5] . As reported previously [27] , APT imaging has great potential in glioma grading, regardless of Gd enhancement. This might further strengthen the advantage of APTW MRI. Third, we used single-slice APT imaging in our initial study. Thus, APT imaging in the present study did not cover the whole tumor. However, this would not affect the comparative results, such as heterogeneity assessment for APT and Gd-enhanced imaging, since the comparative assessment was performed on the same slice among different modalities. This slice was the maximum cross-sectional tumor area based on an on-site decision from an experienced radiologist. The voxel size of our two-dimensional APT imaging was 1.88 × 3.75 × 6 mm, which was similar to that of Gd-enhanced imaging. This comparable spatial resolution made no difference during tumor assessment on APT or Gd-enhanced images. Notably, the clinical availability of fast three-dimensional APT imaging (G 5 min) would help to further streamline clinical PET/MR protocols by covering the whole brain and investigate combined multiparametric analysis by improving APTW measurements [28, 29] . In addition, it is known that calculated APTW signal intensities essentially had the semiquantification characteristic only, primarily due to the contamination of the upfield nuclear Overhauser enhancement (NOE) effect [6] [7] [8] . In addition, amine protons in glutamate (~3 ppm) [9] may also make contributions to APTW signals. Several alternative APTW imaging analysis or acquisition approaches have been proposed to quantify a pure APT effect [10, 11, 30] . Notably, the extrapolated semisolid magnetization transfer reference model developed recently [12, 13] should achieve more pure APT quantification, and we will apply this promising imaging analysis method to our future research. Finally, because of the low concentration of [ 18 F]FDG, we neglected the effect of [ 18 F]FDG on APT imaging. Inorganic fluoride ions should not contribute to the CEST effect. The hydroxyl protons of FDG can be detected by CEST at ultrahigh fields (9 7 T) [31, 32] , but their detectability would be minimal due to the fast exchange property at 3 T. Thus, [ 18 F]FDG may not show any effect on APT imaging, which is based on the concentration of amides.
Conclusion
The results of this hybrid brain [ 18 F]FDG PET/MR study demonstrate that APT imaging not only shows good concordance with Gd-enhanced MRI but also adds value to [ 18 F]FDG PET. Thus, if further studies confirm our findings, a brain PET/MR scan protocol may be streamlined without the need to administer Gd chelates. Compared to [ 18 F]FDG metabolism, the complementary information from the endogenous cellular proteins and peptides in APT imaging might strengthen and extend the clinical applications of PET/MR in tumor diagnosis, treatment planning, and therapy response assessment.
